Case Reports in Hematology / 2018 / Article / Tab 1

Case Report

Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency

Table 1

Coagulation studies of the patient and her two daughters.

Normal rangePatient (91 years)Daughter 1 (66 years)Daughter 2 (54 years)
Period after warfarin cessationPeriod after rivaroxaban
2 weeks4 weeks5 weeks2 weeks3 weeks

Total PS antigen%65–135525457546253
Free PS antigen%60–150253027272925
PS activity%56–126<10
PC activity%64–14640120156131
PT-INR1.110.961.000.890.851.021.10
II%75–13576
VII%75–140146
IX%70–130105
X%70–13085

PS: protein S; PC: protein C; PT-INR: prothrombin time-international normalized ratio.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.